Back to top
more

Invitae Corporation (NVTA)

(Delayed Data from NYSE)

$24.76 USD

24.76
946,453

+0.60 (2.48%)

Updated May 3, 2019 04:02 PM ET

After-Market: $24.77 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Invitae (NVTA) Reports Q4 Loss, Tops Revenue Estimates

Invitae (NVTA) delivered earnings and revenue surprises of -9.46% and 1.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Tracey Ryniec headshot

This Week's 5 Must-See Earnings Charts

Will earnings matter for these 5 trending stocks?

Earnings Preview: Invitae (NVTA) Q4 Earnings Expected to Decline

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Azenta (AZTA) Beats Q1 Earnings and Revenue Estimates

Brooks (AZTA) delivered earnings and revenue surprises of 50% and 3.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Invitae (NVTA) is Poised for a Turnaround After Losing 30.9% in 4 Weeks

Invitae (NVTA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Kevin Cook headshot

Bull of the Day: Mesa Laboratories (MLAB)

Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy

Implied Volatility Surging for Invitae (NVTA) Stock Options

Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.

Invitae (NVTA) Reports Q3 Loss, Lags Revenue Estimates

Invitae (NVTA) delivered earnings and revenue surprises of -17.39% and -8.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Invitae (NVTA) Q3 Earnings Expected to Decline

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Bull of the Day: Mesa Laboratories (MLAB)

Key M&A boosts sales & EPS, opens path to new business with Clinical Genomics Division

PacBio (PACB) Partners with ERGA, Boosts Biodiversity Research

PacBio's (PACB) collaboration with ERGA will help scientists to take the first important step toward creating high-quality genetic maps of each plant and animal species in a reliable manner.

PacBio (PACB) Closes Omniome Buyout, Forays Into San Diego

PacBio's (PACB) latest acquisition is expected to deliver a differentiated set of products and applications across a wide spectrum of markets.

Invitae (NVTA) Reports Q2 Loss, Tops Revenue Estimates

Invitae (NVTA) delivered earnings and revenue surprises of -30.77% and 6.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Kevin Cook headshot

Bear of the Day: NeoGenomics (NEO)

Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff

Will Invitae (NVTA) Report Negative Earnings Next Week? What You Should Know

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PacBio (PACB) Enhances Sequencing Platform Via Latest Buyout

PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.

Kevin Cook headshot

Bull of the Day: Exact Sciences (EXAS)

EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year

Kevin Cook headshot

Tech Bubble 2.0 + Inflation Tsunami: How to Play Them Now

Morgan Stanley warns investors 15% correction coming as market overvalued like dot-com days.

Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know

Invitae (NVTA) closed the most recent trading day at $33.73, moving -1.03% from the previous trading session.

Invitae (NVTA) Outpaces Stock Market Gains: What You Should Know

Invitae (NVTA) closed the most recent trading day at $34.25, moving +1.3% from the previous trading session.

Invitae (NVTA) Gains As Market Dips: What You Should Know

In the latest trading session, Invitae (NVTA) closed at $32.79, marking a +1.52% move from the previous day.

Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Invitae (NVTA) closed at $31.22, marking a -0.22% move from the previous day.

Invitae (NVTA) Outpaces Stock Market Gains: What You Should Know

Invitae (NVTA) closed at $29.95 in the latest trading session, marking a +1.66% move from the prior day.

Invitae (NVTA) Reports Q1 Loss, Tops Revenue Estimates

Invitae (NVTA) delivered earnings and revenue surprises of -5.00% and 1.58%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Invitae (NVTA) to Report Q1 Earnings: What's in the Offing?

Invitae's (NVTA) first-quarter results are likely to reflect strength in genetic testing.